Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Yeda Research and Develpment & Co. Ltd

Dan Grisaru

Hermona Soreq

Zelig Eshhar

Tova Waks

Anat Globerson Levin

Varda Deutsch

Moran Rawet Slobodkin

Varda Deutch

Naamit Deshet-unger

Chava Perry

Ben Zion Katz

Marjorie Pick

Ido Laskov

Sofia Eldor, Legal Representative

The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.

T-cells comprising two different chimeric antigen receptors and uses thereof

The present invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. In addition, the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines is also presented. ARP may further be used in the pre-transplant priming of hematopoietic stem cells. Other uses and methods utilizing ARP are also described herein.

Acetylcholinesterase (ACHE)-derived peptide as an inducer of granulocytopoiesis, uses and methods thereof

The invention relates to a cell growth and/or differentiation regulatory peptide comprising a sequence of about 9 to about 150 amino acids derived from acetylcholinesterase amino acid sequence, preferably from the C-terminal region of acetylcholinesterase. The invention also relates to pharmaceutical compositions comprising the peptides, particularly for use in promoting survival of stem cells, promoting differentiation of stem cells, promoting growth of stem cells and/or promoting the growth-enhancing effect of a growth factor on stem cells, alone, or in combination with other growth factors. Of particular interest is the use of the peptides in the treatment of thrombocytopenia, post-irradiation conditions, post-chemotherapy conditions, or conditions following massive blood loss and promotion of neural progenitors in use for cell therapies aimed at restoring neural functions in diseased individuals. Further, the invention relates to antibodies against the peptides, inter alia for diagnostic use, for example, the diagnosis of stress-induced male infertility. The invention also relates to in vitro and in vivo methods for screening of drugs that affect the central nervous system, and are potential modulators of interactions between the 'readthrough' form of acteylcholinesterase, AChE-R, the intracellular receptor RACK1 and the kinase PKC.

Acetylcholinesterase-derived peptides and uses thereof

Growing community of inventors

Herzliya, Israel

Dan Grisaru